Abstract
The theoretical amorphous solubility enhancement ratio (Rs) can be calculated based on the free energy difference between amorphous and crystalline forms (ΔGx→a), using several experimentally determined input parameters. This work compares the various approaches for the calculation of Rs and explores the nuances associated with its calculation. The uncertainty of Rs values owing to experimental conditions (differential scanning calorimetry heating rates) used to measure the input parameters was determined for 3 drugs (indomethacin, itraconazole, and spironolactone). The calculated value of Rs was most influenced by the measurement of heat of fusion. The range in values of Rs using the various equations in the literature was within the calculated uncertainty of the theoretical Rs value. Still, all equations appear to overpredict the experimental value of Rs, sometimes by more than a factor of 5, when an experimental value is attainable. Methods for the calculation of ΔGx→a for molecules undergoing additional phase transitions (other than glass transition and melting) were developed, employing itraconazole as a model drug. In addition, the influences of enthalpy relaxation and entropy of mixing for racemic compounds on Rs were also considered. These additional corrections improved agreement between theoretical and experimental Rs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
